Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

The G8 score is an independent prognostic factor for OS but not PFS in mRCC patients receiving first-line ipilimumab-nivolumab. The Meet-URO score shows consistent prognostic ability for PFS and OS across age groups. These findings suggest that while G8 may be useful for individual patient-level OS prediction, the Meet-URO score may be superior for guiding treatment decisions in clinical practice.

Authors

Institutions

Publication Details

Journal
Technology in Cancer Research & Treatment
Published
2025-02-24
DOI
https://doi.org/10.1177/15330338251316626
Citations
1
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

Lucia Fratino, Fabio Calabrò, Matteo Santoni, Alessio Signori et al.
1 citations
Technology in Cancer Research & Treatment
Renal cell carcinoma treatment
1.52
article

Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

Lucia Fratino, Fabio Calabrò, Matteo Santoni, Alessio Signori, Davide Bimbatti, Marina Campione, Mimma Rizzo, Sara Elena Rebuzzi, Sergio Bracarda, Ugo De Giorgi, Ria Nagpal, Giuseppe Fornarini, Umberto Basso, Diana Giannarelli, Giuseppe Luigi Banna, Pasquale Rescigno
article en
1 citations

Abstract

The G8 score is an independent prognostic factor for OS but not PFS in mRCC patients receiving first-line ipilimumab-nivolumab. The Meet-URO score shows consistent prognostic ability for PFS and OS across age groups. These findings suggest that while G8 may be useful for individual patient-level OS prediction, the Meet-URO score may be superior for guiding treatment decisions in clinical practice.

Technology in Cancer Research & TreatmentVol. 24
Università degli Studi di Enna Kore (IT), Agostino Gemelli University Polyclinic (IT), Ospedale San Paolo (IT), Portsmouth Hospitals NHS Trust (GB), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Istituto Oncologico Veneto (IT), Azienda Ospedaliera S.Maria (IT), Centro di Riferimento Oncologico (IT), Ospedale Policlinico San Martino (IT), Candiolo Cancer Institute (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Ospedale di Macerata, University of Bari Aldo Moro (IT), University of Portsmouth (GB), University of Genoa (IT), Newcastle University (GB)
Good health and well-being
Openalex Percentile: Top 22%
Renal cell carcinoma treatment
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.